ArticleThe Journal of pediatrics2016
Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients.
Article in The Journal of pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Pooled it
- Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens).Journal of medical ultrasonics (2001) · 2021Pooled it
- Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy.Frontiers in pediatrics · 2021Pooled it
- Metabolomic Phenotype of Hepatic Steatosis and Fibrosis in Mexican Children Living with Obesity.Medicina (Kaunas, Lithuania) · 2023Trial
- Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.Obesity surgery · 2018Trial
- European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) steatotic liver disease special interest group position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction-associated steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Characteristics of Transient Elastography for Hepatic Steatosis and Fibrosis in Children Undergoing Liver Biopsy.The Journal of pediatrics · 2026Article
- Starting Age for Screening Metabolic Dysfunction-Associated Steatotic Liver Disease in Children Using Controlled Attenuation Parameter on Transient Elastography.Pediatric obesity · 2026Article
- Serum LEAP-2 as a Potential Biomarker for Hepatic Steatosis in Adolescents with Obesity and MASLD: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2025Article
- Screening for metabolic-associated fatty liver disease in type 2 diabetes patients using non-invasive scores and ultrasound: a cross-sectional study in Egypt.BMC gastroenterology · 2025Article
- Ultrasound innovations in abdominal radiology: techniques and clinical applications in pediatric imaging.Abdominal radiology (New York) · 2025Review
- Metabolic and Hepatic Profiles of Non-Obese and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents: The Role of FibroScan Parameters,Fibroblast Growth Factor-21, and Cytokeratin-18.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- The evolving landscape of pediatric obesity and metabolic dysfunction-associated steatotic liver disease.Frontiers in pediatrics · 2025Review
- Impact of Comorbid Polycystic Ovary Syndrome on Clinical and Laboratory Parameters in Female Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study.Journal of clinical medicine · 2024Article
- Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.Hepatology international · 2024Review
- Controlled attenuation parameter (CAP): the clinical value based on MRI-PDFF in children with obesity.Journal of pediatric endocrinology & metabolism : JPEM · 2024Article
- Use of transient elastography to assess hepatic steatosis and fibrosis in patients with juvenile idiopathic arthritis during methotrexate treatment.Clinical rheumatology · 2024Article
- Clinical research of fibroscan ‒ TE-CAP at noninvasive diagnosis of hepatic steatosis in children.Clinics (Sao Paulo, Brazil) · 2024Article
- Liver transient elastography values in healthy South African children.BMC pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess whether the degree of steatosis as determined by controlled attenuation parameter (CAP) measurements correlates with that observed on liver biopsies in a single-center pediatric and young adult cohort. STUDY
designThis cross-sectional study included patients undergoing liver biopsy as part of standard clinical care between January 25, 2012, and April 1, 2015, at Boston Children's Hospital. Eligible patients, with a variety of liver diseases, had CAP measurements within 1 year of biopsy. CAP values were compared across histologic steatosis grades using ANOVA.
resultsSixty-nine patients (mean age, 16.0 ± 2.9 years; 62% male) were studied. CAP measurements were obtained at a median of 1.3 months (IQR, 0.5-3.2) after biopsy. Of the 69 subjects, 23 had steatosis on biopsy. Mean CAP value (dB/m) for subjects with no steatosis was 198 ± 37 vs 290 ± 47 for subjects with steatosis (P < .0001). There were statistically significant differences between CAP values in individuals with no steatosis vs mild/moderate steatosis (P < .0001), no steatosis vs marked steatosis (P < .0001), and mild/moderate vs marked steatosis (P = .004).
conclusionThis study demonstrated a difference in CAP between no steatosis and steatosis, and between grades of steatosis. CAP may be a useful noninvasive tool to detect hepatic steatosis in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.